Therapies with broad yet targeted clinical utility
At Ayala, our work maps back to one underlying goal: Develop and commercialize therapies that improve treatment outcomes for people living with aggressive cancers.
By building a pipeline of gamma secretase inhibitors (GSIs) with broad yet targeted clinical utility, we aim to serve patient populations in need of better cancer therapies. Our investigational product candidates have been, and are currently still being, evaluated in clinical trials at leading oncology centers across the United States, Europe and Canada.
1 Ayala will be entitled to receive an exercise fee and potentially certain development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales of licensed products, if Novartis exercises its option to license AL102 for the treatment of MM. Phase 1 study with bi-specific anti-BCMA is ongoing but dosing of AL102 has not yet been initiated.
R/M ACC = Recurring / Metastatic Adenoid Cystic Carcinoma
R/M TNBC = Recurring / Metastatic Triple Negative Breast Cancer
R/R T-ALL = Relapsed / Refractory T-cell Acute Lymphoblastic Leukemia
MM = Multiple Myeloma
BCMA = B-cell Maturation Antigen
Using our deep understanding of the Notch pathway, we develop precise therapies to address the underlying key drivers of tumor growth in patients where GSI inhibition of Notch can lead to clinical benefit.